Omega 3 fatty acid treatment in patients with epilepsy

Omega 3 fatty acid supplementation to prevent seizure in patients with refractory epilepsy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN57643242

Enrollment

Registered

2014-08-20

Start date

2014-09-01

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy Nervous System Diseases Epilepsy

Interventions

1. Active supplement (contains 1.5g DHA and 390mg EPA) 2. Placebo (1.9g of saturated and monounsaturated fatty acid blend)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with refractory idiopathic epilepsy, aged 17 to 50 years

Exclusion criteria

Exclusion criteria: 1. Age under 17 and over 50 years 2. Other diseases in addition to epilepsy 3. Structural lesions 4. Pregnancy 5. Responsive to AED 6. Less than two seizures a month

Design outcomes

Primary

Measure	Time frame
Complete elimination or reduction in the frequency seizures	—

Secondary

Measure	Time frame
1. Improvements of cognition, memory, and manifestations of behavioural and psychiatric disorders 2. Modulation of clinical markers of cardiac arrhythmias; down regulation of inflammatory markers	—

Countries

Sudan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026